Top Gastroparesis Drugs Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Gastroparesis Drugs Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Gastroparesis Drugs industry players.

Gastroparesis Drugs Market Competitive Landscape

The competitive landscape of the global gastroparesis drugs industry in 2024 is characterized by ongoing advancements in drug development, strategic collaborations, and an increasing focus on patient-centered treatments. Key players in the market, such as AbbVie, Boston Scientific, and Takeda Pharmaceuticals, are actively involved in the research and development of new therapies.

As per market strategies, in 2024, AbbVie continued to expand its portfolio through strategic partnerships, focusing on innovative treatments for gastrointestinal disorders, including gastroparesis. For instance, the company recently entered a collaboration with a biotech firm to develop novel prokinetic agents aimed at improving gastric motility in gastroparesis patients.

The gastroparesis drugs market has seen significant innovation and development, especially with the emergence of several startups focused on addressing the unmet needs of patients suffering from delayed gastric emptying. These startups, founded after 2018, are leveraging cutting-edge biotechnology to develop novel treatments that target the underlying causes of gastroparesis. Their approach includes advancing both prokinetic agents and alternative therapies that improve gastric motility, with a particular focus on oral formulations that enhance patient compliance.

  • Motus Therapeutics (Founded in 2019): Motus Therapeutics is a biotech startup focused on developing innovative treatments for gastrointestinal disorders, including gastroparesis. The company’s lead drug candidate targets the root causes of gastric motility disorders and aims to improve treatment efficacy for patients suffering from delayed gastric emptying, a key symptom of gastroparesis.
  • Mediomics (Founded in 2020): Mediomics is a startup dedicated to advancing the treatment of chronic gastrointestinal conditions, including gastroparesis. The company is developing a novel class of drugs designed to enhance gastrointestinal motility while minimizing side effects associated with traditional prokinetic agents. Mediomics aims to bring more effective and patient-friendly options to the market, especially focusing on oral formulations.

Top Player’s Company Profile

  • AbbVie
  • Evoke Pharma
  • Vanda Pharmaceuticals
  • Renexxion Ireland Limited
  • Celerion
  • AstraZeneca
  • GSK (GlaxoSmithKline)
  • Ironwood Pharmaceuticals
  • Takeda Pharmaceutical
  • UCB Pharma
  • Valeant Pharmaceuticals
  • Progenics Pharmaceuticals
  • Meda AB (Acquired by Mylan)
  • Synergy Pharmaceuticals (Acquired by Bausch Health)
  • Mallinckrodt Pharmaceuticals

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Gastroparesis Drugs Market size was valued at USD 6.01 Billion in 2024 and is poised to grow from USD 6.34 Billion in 2025 to USD 9.74 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026–2033). 

The competitive landscape of the global gastroparesis drugs industry in 2024 is characterized by ongoing advancements in drug development, strategic collaborations, and an increasing focus on patient-centered treatments. Key players in the market, such as AbbVie, Boston Scientific, and Takeda Pharmaceuticals, are actively involved in the research and development of new therapies. 'AbbVie Inc. (USA) ', 'Evoke Pharma, Inc. (USA) ', 'Vanda Pharmaceuticals Inc. (USA) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'AstraZeneca PLC (UK) ', 'GlaxoSmithKline PLC (GSK) (UK) ', 'Neurogastrx Inc. (USA) ', 'Processa Pharmaceuticals, Inc. (USA) ', 'Abbott Laboratories (USA) ', 'Bausch Health Companies Inc. (Canada) ', 'Rhythm Pharmaceuticals, Inc. (USA) ', 'CinDome Pharma (USA) ', 'ANI Pharmaceuticals, Inc. (USA) ', 'Johnson & Johnson Inc. (USA) ', 'Pfizer Inc. (USA) ', 'Teva Pharmaceutical Industries Ltd. (Israel) ', 'Medtronic PLC (Ireland) ', 'Otsuka Pharmaceutical Co. Ltd. (Japan) ', 'Theravance Biopharma, Inc. (USA) ', 'Cadila Pharmaceuticals (India) '

A key driver for the market is the rising incidence of diabetes, which is closely linked to gastroparesis. As more individuals develop Type 1 and Type 2 diabetes globally, complications like diabetic gastroparesis are becoming more common, necessitating medical intervention. In January 2024, the International Diabetes Federation reported a noticeable uptick in global diabetic cases, especially in Asia and North America, pushing pharmaceutical companies like Evoke Pharma to ramp up production of drugs like Gimoti, targeting diabetic gastroparesis.

AI-Powered Drug Discovery and Trial Design: Artificial intelligence is becoming an integral part of pharmaceutical R&D, especially for complex disorders like gastroparesis, which lack a one-size-fits-all treatment. AI helps in identifying molecular targets, simulating drug interactions, and optimizing clinical trial protocols. In March 2024, Quris-AI collaborated with NeuroGasTx to streamline its gastroparesis clinical trial strategy using AI-powered patient simulation models. This reduced trial costs and increased enrollment efficiency by 25%, improving speed-to-market for their new neuromodulating drug.

As per regional forecast, North America holds a significant share of the global gastroparesis drugs market, driven by the high prevalence of gastroparesis in the region and well-established healthcare infrastructure. The U.S. accounts for the largest market share, fueled by the growing demand for drugs to treat chronic gastrointestinal disorders, including gastroparesis. Canada follows with steady growth in the market as awareness of gastroparesis and treatment options continues to increase. The robust healthcare system, strong reimbursement policies, and the presence of key pharmaceutical companies contribute to the region’s dominance in the market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Gastroparesis Drugs Market
Gastroparesis Drugs Market

Report ID: SQMIG35I2378

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE